Integrated Quantitative Investments LLC Buys New Holdings in Grifols, S.A. $GRFS

Integrated Quantitative Investments LLC bought a new position in Grifols, S.A. (NASDAQ:GRFS) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 136,678 shares of the biotechnology company’s stock, valued at approximately $1,361,000.

A number of other hedge funds also recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Grifols by 2.4% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock valued at $427,000 after acquiring an additional 1,114 shares in the last quarter. Versant Capital Management Inc lifted its stake in Grifols by 39.5% during the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,584 shares during the period. Merit Financial Group LLC boosted its holdings in Grifols by 14.1% during the third quarter. Merit Financial Group LLC now owns 13,978 shares of the biotechnology company’s stock valued at $139,000 after purchasing an additional 1,728 shares in the last quarter. Savant Capital LLC raised its holdings in shares of Grifols by 16.0% in the 3rd quarter. Savant Capital LLC now owns 14,011 shares of the biotechnology company’s stock worth $140,000 after buying an additional 1,935 shares in the last quarter. Finally, Ascent Group LLC lifted its position in shares of Grifols by 12.5% during the 3rd quarter. Ascent Group LLC now owns 17,597 shares of the biotechnology company’s stock worth $175,000 after buying an additional 1,951 shares during the period.

Analysts Set New Price Targets

Several research firms have issued reports on GRFS. JPMorgan Chase & Co. dropped their price objective on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Wall Street Zen lowered shares of Grifols from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Four analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Grifols Stock Performance

GRFS opened at $8.66 on Thursday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.88 and a current ratio of 2.51. Grifols, S.A. has a 52-week low of $6.19 and a 52-week high of $11.14. The firm has a market cap of $5.95 billion, a P/E ratio of 45.58, a price-to-earnings-growth ratio of 0.30 and a beta of 0.67. The business’s fifty day moving average is $9.20 and its 200-day moving average is $9.31.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.